MAP2K7 and melanoma: These studies were undertaken because MEK inhibitors have been developed for human use [22]–[25], and the MEK inhibitor, trametinib (GSK1120212), has been recently approved by the U.S. Food and Drug Administration (FDA) for treatment of melanoma [24], [25].